Evidence map›Paper›PMID 37038131›Full record

ArticleThe journal of headache and pain2023

Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain.

Adriana Della Pietra, Georgii Krivoshein, Konstantin Ivanov, Raisa Giniatullina, Henna-Kaisa Jyrkkänen, Ville Leinonen, Marko Lehtonen, Arn M J M van den Maagdenberg, Juha Savinainen, Rashid Giniatullin

Open access · goldAbstract read
In one paragraph

Article in The journal of headache and pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Overlapping pathways of migraine and the endocannabinoid system: Potential therapeutic targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. International journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Adriana Della Pietra *A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Georgii Krivoshein *A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Konstantin IvanovInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Raisa GiniatullinaA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Henna-Kaisa JyrkkänenDepartment of Neurosurgery, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Ville LeinonenDepartment of Neurosurgery, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Marko LehtonenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Arn M J M van den MaagdenbergDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Juha SavinainenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Rashid GiniatullinA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. rashid.giniatullin@uef.fi.
University of Eastern Finland · FILeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEngaging the endocannabinoid system through inhibition of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), degrading endocannabinoids (endoCBs) 2-arachidonoylglycerol (2-AG) and anandamide (AEA), was proposed as a promising approach to ameliorate migraine pain. However, the activity of MAGL and FAAH and action of endoCB on spiking activity of meningeal afferents, from which migraine pain originates, has not been explored thus far. Therefore, we here explored the analgesic effects of endoCB enhancement in rat and human meningeal tissues.

methodsBoth MAGL and FAAH activity and local 2-AG and AEA levels were measured by activity-based protein profiling (ABPP) and LC-MS/MS, respectively, in rat meninges obtained from hemiskulls of P38-P40 Wistar rats and human meninges from elderly patients undergoing non-migraine related neurosurgery. The action on endoCBs upon administration of novel dual MAGL/FAAH inhibitor AKU-005 on meningeal afferents excitability was tested by investigating paired KCl-induced spiking and validation with local (co-)application of either AEA or 2-AG. Finally, the specific TRPV1 agonist capsaicin and blocker capsazepine were tested.

resultsThe basal level of 2-AG exceeded that of AEA in rat and human meninges. KCl-induced depolarization doubled the level of AEA. AKU-005 slightly increased spontaneous spiking activity whereas the dual MAGL/FAAH inhibitor significantly decreased excitation of nerve fibres induced by KCl. Similar inhibitory effects on meningeal afferents were observed with local applications of 2-AG or AEA. The action of AKU-005 was reversed by CB1 antagonist AM-251, implying CB1 receptor involvement in the anti-nociceptive effect. The inhibitory action of AEA was also reversed by AM-251, but not with the TRPV1 antagonist capsazepine. Data cluster analysis revealed that both AKU-005 and AEA largely increased long-term depression-like meningeal spiking activity upon paired KCl-induced spiking.

conclusionsIn the meninges, high anti-nociceptive 2-AG levels can tonically counteract meningeal signalling, whereas AEA can be engaged on demand by local depolarization. AEA-mediated anti-nociceptive effects through CB1 receptors have therapeutic potential. Together with previously detected MAGL activity in trigeminal ganglia, dual MAGL/FAAH inhibitor AKU-005 appears promising as migraine treatment.

Indexed as

EndocannabinoidsMigraine DisordersAgedAmidohydrolasesAnimalsCapsaicinCarbamatesChromatography, LiquidFatty Acid Amide HydrolasesHumansMonoacylglycerol LipasesMonoglyceridesNociceptionPainRatsRats, WistarAmidohydrolasesCapsaicincapsazepineCarbamatesEndocannabinoidsFatty Acid Amide HydrolasesMonoacylglycerol LipasesMonoglycerides2-arachidonoylglycerolAnandamideHeadacheNeuronal firing

Identifiers

PMID37038131
PMCPMC10088116
OpenAlexW4363678655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.